

Certificate of Amalgamation

Certificat de fusion

Canada Business Corporations Act

Loi canadienne sur les sociétés par actions

Medexus Pharmaceuticals Inc.

Corporate name / Dénomination sociale

1288431-3

Corporation number / Numéro de société

I HEREBY CERTIFY that the above-named corporation resulted from an amalgamation, under section 185 of the *Canada Business Corporations Act*, of the corporations set out in the attached articles of amalgamation.

JE CERTIFIE que la société susmentionnée est issue d'une fusion, en vertu de l'article 185 de la *Loi canadienne sur les sociétés par actions*, des sociétés dont les dénominations apparaissent dans les statuts de fusion ci-joints.

Raymond Edwards

Recues S

Director / Directeur

2021-04-01

Date of Amalgamation (YYYY-MM-DD)

Date de fusion (AAAA-MM-JJ)



Innovation, Sciences et Développement économique Canada Corporations Canada

Canada Business Corporations Act (CBCA) FORM 9 ARTICLES OF AMALGAMATION (Section 185)

1 - Corporate name of the amalgamated corporation			
Medexus Pharmaceuticals Inc.			
2 - The province or territory in Canada where the registered office is situated (do not indicate the full address)			
Ontario			
3 - The classes and any maximum number of shares that the An unlimited number of common shares and an unlimited number of	•		
4 - Restrictions, if any, on share transfers			
No restrictions			
5 - Minimum and maximum number of directors (for a fixed number of directors, please indicate the same number in both boxes)			
Minimum number 3	Maximum number 1	5	
6 - Restrictions, if any, on the business the corporation may carry on			
None			
7. 04			
7 - Other provisions, if any See Schedule "B" attached hereto			
8 - The amalgamation has been approved pursuant to that section or subsection of the Act which is indicated as follows:			
	cal short-form : oved by resolution of tors	184(2) - Horizontal short-form : approved by resolution of directors	
9 - Declaration			
I hereby certify that I am a director or an authorized officer of th	e following corporation:		
Name of the amalgamating corporations	Corporation number	Signature	
Medexus Pharmaceuticals Inc.	8 6 8 5 1 2 - 6		
Medexus Inc.	1 1 0 4 6 1 3 - 6	//	
Nata Missans and the same of t	lation and the Baltine	Single and acceptable of COOC and a long days of Cook	
Note: Misrepresentation constitutes an offence and, on summary conviterm not exceeding six months or to both (subsection 250(1) of the converse of the convers	the CBCA).	a line not exceeding \$5,000 or to imprisonment for a	



SCHEDULE "A" TO ARTICLES OF AMALGAMATION

The Corporation is authorized to issue:

- an unlimited number of common shares: and
- an unlimited number of preferred shares (issuable in series);

having attached thereto the rights, privileges, restrictions and conditions hereinafter set forth.

COMMON SHARES

There shall be attached to the common shares, the following rights, privileges, restrictions and conditions, namely:

- 1. The holders of common shares shall be entitled to receive notice of, and to vote at every meeting of the shareholders of the Corporation and shall have one (1) vote thereat for each such common share so held.
- 2. Subject to the rights, privileges, restrictions and conditions attached to any preferred shares of the Corporation, the holders of common shares shall be entitled to receive such dividend as the directors may from time to time, by resolution, declare.
- 3. Subject to the rights, privileges, restrictions and conditions attached to any preferred shares of the Corporation, in the event of liquidation, dissolution or winding up of the Corporation or upon any distribution of the assets of the Corporation among shareholders being made (other than by way of dividend out of monies properly applicable to the payment of dividends) the holders of common shares shall be entitled to share pro rata.

PREFERRED SHARES (ISSUABLE IN SERIES)

There shall be attached to the preferred shares, the following rights, privileges, restrictions, and conditions, namely:

- The directors of the Corporation may, from time to time, issue the preferred shares in one or more series, each series to consist of such number of shares as may before issuance thereof, be determined by the directors.
- 2. The directors of the Corporation may, by resolution (subject as hereinafter provided) fix before issuance, the designation, rights, privileges, restrictions and conditions to attach to the preferred shares of each series, including, without limiting the generality of the foregoing, the rate, form, entitlement and payment of preferential dividends, the redemption price, terms, procedures and conditions of redemption, if any, voting rights and conversion rights (if any) and any sinking fund, purchase fund or other provisions attaching to the preferred shares of such series; and provided however, that no shares of any series shall be issued until the directors have filed Articles of Amendment with the Director of Corporations Canada, Industry Canada, or such designated person in any other jurisdiction in which the Corporation may be continued.
- 3. If any cumulative dividends or amounts payable on return of capital in respect of a series of shares are not paid in full, the shares of all series shall participate ratably in respect of accumulated dividends and return of capital.
- 4. The preferred shares shall be entitled to preference over the common shares of the Corporation and any other shares of the Corporation ranking junior to the preferred shares with respect to the payment of dividends, if any, and in the distribution of assets in the event of liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary, or any other

distribution of the assets of the Corporation among its shareholders for the purpose of winding up its affairs, and may also be given such other preferences over the common shares of the Corporation and any other shares of the Corporation ranking junior to the preferred shares as may be fixed by the resolution of the directors of the Corporation as to the respective series authorized to be issued.

- 5. The preferred shares of each series shall rank on a parity with the preferred shares of every other series with respect to priority in the payment of dividends and in the distribution of assets in the event of liquidation, dissolution or winding up of the Corporation, whether voluntary exclusive of any conversion rights that may affect the aforesaid.
- 6. No dividends shall at any time be declared or paid on or set apart for payment on any shares of the Corporation ranking junior to the preferred shares unless all dividends, if any, up to and including the dividend payable for the last completed period for which such dividend shall be payable on each series of preferred shares then issued and outstanding shall have been declared and paid or set apart for payment at the date of such declaration or payment or setting apart for payment on such shares of the Corporation ranking junior to the preferred shares nor shall the Corporation call for redemption or redeem or purchase for cancellation or reduce or otherwise pay off any of the preferred shares (less than the total amount then outstanding) or any shares of the Corporation ranking junior to the preferred shares unless all dividends up to and including the dividend payable, if any, for the last completed period for which such dividends shall be payable on each series of the preferred shares then issued and outstanding shall have been declared and paid or set apart for payment at the date of such call for redemption, purchase, reduction or other payment
- 7. Preferred shares of any series may be purchased for cancellation or made subject to redemption by the Corporation out of capital pursuant to the provisions of the *Canada Business Corporations Act*, if the directors so provide in the resolution of the Board of Directors of the Corporation relating to the issuance of such preferred shares, and upon such other terms and conditions as may be specified in the designations, rights, privileges, restrictions and conditions attaching to the preferred shares of such series as set forth in the said resolution of the Board of Directors and the Articles of Amendment of the Corporation relating to the issuance of such series.
- 8. The holders of the preferred shares shall not, as such, be entitled as of right to subscribe for or purchase or receive any part of any issue of shares or bonds, debentures or other securities of the Corporation now or hereafter authorized.
- 9. No class of shares may be created or rights and privileges increased to rank in parity or priority with the rights and privileges of the preferred shares including, without limiting the generality of the foregoing, the rights of the preferred shares to receive dividends or to return of capital, without the approval of the holders of the preferred shares as required under the *Canada Business Corporations Act*.

SCHEDULE "B" TO ARTICLES OF AMALGAMATION

OTHER PROVISIONS

1. Lien on Shares

The Corporation has a lien on the shares registered in the name of a shareholder or his legal representative for a debt of that shareholder to the Corporation. The Corporation may enforce such lien in accordance with its By-laws.

2. Appointments of Directors

The directors may appoint one or more additional directors of the Corporation, who shall hold office for a term expiring not later than the close of the next annual meeting of shareholders, but the total number of directors so appointed may not exceed one third of the number of directors elected at the previous annual meeting of shareholders.

Form 2 Initial Registered Office Address and First Board of Directors

Canada Business Corporations Act (CBCA) (s. 19 and 106)

Formulaire 2 Siège social initial et premier conseil d'administration

Loi canadienne sur les sociétés par actions (LCSA) (art. 19 et 106)

1	Corporate name Dénomination sociale
	Medexus Pharmaceuticals Inc.
2	Address of registered office Adresse du siège social
	35 Nixon Road, Suite 1 Bolton ON L7E 1K1
3	Additional address Autre adresse
4	Members of the board of directors Membres du conseil d'administration See attached schedule / Voir l'annexe ci-jointe
5	Declaration: I certify that I have relevant knowledge and that I am authorized to sign this form. Déclaration: J'atteste que je possède une connaissance suffisante et que je suis autorisé(e) à signer le présent formulaire.
	Original signed by / Original signé par Roland Boivin
	Roland Boivin 514-796-2640

Misrepresentation constitutes an offence and, on summary conviction, a person is liable to a fine not exceeding \$5000 or to imprisonment for a term not exceeding six months or both (subsection 250(1) of the CBCA).

Faire une fausse déclaration constitue une infraction et son auteur, sur déclaration de culpabilité par procédure sommaire, est passible d'une amende maximale de 5 000 \$ et d'un emprisonnement maximal de six mois, ou l'une de ces peines (paragraphe 250(1) de la LCSA).

You are providing information required by the CBCA. Note that both the CBCA and the *Privacy Act* allow this information to be disclosed to the public. It will be stored in personal information bank number IC/PPU-049.

Vous fournissez des renseignements exigés par la LCSA. Il est à noter que la LCSA et la Loi sur les renseignements personnels permettent que de tels renseignements soient divulgués au public. Ils seront stockés dans la banque de renseignements personnels numéro IC/PPU-049.



Schedule / Annexe Members of the board of directors / Membres du conseil d'administration

Resident Canadian Résident Canadien

Adele M. Gulfo

No / Non

Yes / Oui

Peter van der Velden

Michael P. Mueller

Stephen Nelson

Yes / Oui

Yes / Oui

Yes / Oui